Protease Inhibitors (PIs)
Last Updated: May 22, 2018; Last Reviewed: May 22, 2018
Indinavir (IDV, Crixivan)
|Indinavir (IDV, Crixivan)
For additional information see Drugs@FDA: https://www.accessdata.fda.gov/scripts/cder/daf/
|Capsules: 100 mg, 200 mg, and 400 mg
||Selected Adverse Events
|Neonate and Infant Dose:
- Not approved for use in neonates/infants
- Should not be administered to neonates because of the risks associated with hyperbilirubinemia (kernicterus)
Adolescent and Adult Dose:
- Not approved for use in children
- A range of indinavir doses (234–500 mg/m2 body surface area) boosted with low-dose ritonavir has been studied in children (see text below).
- 800 mg indinavir plus 100 or 200 mg ritonavir every 12 hours
- The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV does not recommend the use of indinavir in adolescents.
- Gastrointestinal intolerance, nausea
- Indirect hyperbilirubinemia
- Fat maldistribution
- Possible increased bleeding episodes in patients with hemophilia
- When indinavir is given in combination with ritonavir, meal restrictions are not necessary.
- Adequate hydration is required to minimize risk of nephrolithiasis (≥48 oz of fluid daily in adult patients).
- Indinavir capsules are sensitive to moisture; store at room temperature (59–86ºF) in original container with desiccant.
Indinavir Dosing in Patients with Hepatic Impairment:
- Cytochrome P450 3A4 (CYP3A4) inhibitor and substrate
- Dose should be decreased in patients with mild-to-moderate hepatic impairment (recommended dose for adults is 600 mg indinavir every 8 hours). No dosing information is available for children with any degree of hepatic impairment or for adults with severe hepatic impairment.